Skip to main content

Table 2 Percentage of patients obtaining low disease activity or remission at year 7 at the time of discontinuation

From: Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity

 

Mean DAS (SE)

Low disease activity

Remission

At year 7 (still on infliximab)

3.0 (0.1)

60.90%

45.50%

At discontinuation due to ineffectiveness

5.2 (0.2)

10.50%

5.30%

At discontinuation due to elective reason

2.9 (0.1)

61.70%

46.70%

At discontinuation due to safety issue

4.3 (0.7)

33.30%

13.60%

  1. DAS: Disease Activity Score; SE: standard error.